625 related articles for article (PubMed ID: 9645167)
1. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma.
Rodriguez M
Acta Radiol Suppl; 1998; 417():1-36. PubMed ID: 9645167
[TBL] [Abstract][Full Text] [Related]
2. [18F] FDG PET in gastric non-Hodgkin's lymphoma.
Rodriguez M; Ahlström H; Sundín A; Rehn S; Sundström C; Hagberg H; Glimelius B
Acta Oncol; 1997; 36(6):577-84. PubMed ID: 9408147
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.
Ambrosini V; Rubello D; Castellucci P; Nanni C; Farsad M; Zinzani P; Alavi A; Tehranipour N; Al-Nahhas A; Fanti S
Nucl Med Rev Cent East Eur; 2006; 9(1):37-40. PubMed ID: 16791802
[TBL] [Abstract][Full Text] [Related]
4. Predicting malignancy grade with PET in non-Hodgkin's lymphoma.
Rodriguez M; Rehn S; Ahlström H; Sundström C; Glimelius B
J Nucl Med; 1995 Oct; 36(10):1790-6. PubMed ID: 7562044
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma.
Yi JH; Kim SJ; Choi JY; Ko YH; Kim BT; Kim WS
Hematol Oncol; 2010 Jun; 28(2):57-61. PubMed ID: 19593742
[TBL] [Abstract][Full Text] [Related]
6. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
8. CT in malignancy grading and prognostic prediction of non-Hodgkin's lymphoma.
Rodriguez M; Rehn SM; Nyman RS; Sundström JC; Ahlström H; Glimelius BL
Acta Radiol; 1999 Mar; 40(2):191-7. PubMed ID: 10080733
[TBL] [Abstract][Full Text] [Related]
9. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
10. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.
Jerusalem GH; Beguin YP
Clin Lymphoma; 2002 Jun; 3(1):56-61. PubMed ID: 12141957
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
13. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma.
Zijlstra JM; Hoekstra OS; Raijmakers PG; Comans EF; van der Hoeven JJ; Teule GJ; Jonkhoff AR; v Tinteren H; Lammertsma AA; Huijgens PC
Br J Haematol; 2003 Nov; 123(3):454-62. PubMed ID: 14617005
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
15. Differential Diagnosis of Sinonasal Lymphoma and Squamous Cell Carcinoma on CT, MRI, and PET/CT.
Kim SH; Mun SJ; Kim HJ; Kim SL; Kim SD; Cho KS
Otolaryngol Head Neck Surg; 2018 Sep; 159(3):494-500. PubMed ID: 29661053
[TBL] [Abstract][Full Text] [Related]
16. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
[TBL] [Abstract][Full Text] [Related]
17. Nodal staging of lymphoma with whole-body PET: comparison of.
Sutinen E; Jyrkkiö S; Varpula M; Lindholm P; Grönroos T; Lehikoinen P; Teräs M; Minn H
J Nucl Med; 2000 Dec; 41(12):1980-8. PubMed ID: 11138682
[TBL] [Abstract][Full Text] [Related]
18. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.
Albano D; Bertoli M; Ferro P; Fallanca F; Gianolli L; Picchio M; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):589-597. PubMed ID: 27619357
[TBL] [Abstract][Full Text] [Related]
20. Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour.
Graziosi L; Bugiantella W; Cavazzoni E; Cantarella F; Porcari M; Baffa N; Donini A
Ann Ital Chir; 2011; 82(2):125-9. PubMed ID: 21682102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
